The 4 most recent market catalysts affecting $CAMP, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 10, 2026
Corporate Catalyst
Bullish
Impact 65
CAMP4 Therapeutics Receives MHRA Authorization To Include UK Sites In Global Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic Candidate For Patients With SYNGAP1-Related Disorder
CAMP4 Therapeutics announced that it has secured authorization from the UK's MHRA to include UK sites in its global Phase 1/2 clinical trial for CMP-002, a drug targeting SYNGAP1-r…
Aug 14, 2026
Corporate Catalyst
Bullish
Impact 75
CAMP4 Therapeutics shares are trading higher after Piper Sandler reiterated its Overweight rating on the stock and raised its price target from $12 to $15.
The headline indicates a significant positive catalyst for CAMP4 Therapeutics, as a prominent analyst firm has not only maintained a bullish rating but also raised its price target…
Aug 13, 2026
Corporate Catalyst
Bearish
Impact 95
Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate
Camp4 Therapeutics announced its Q2 earnings, revealing a substantial miss on analyst expectations for both earnings per share and sales. The reported loss of $(0.58) per share was…
Jul 27, 2026
Corporate Catalyst
Bullish
Impact 65
CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder
CAMP4 Therapeutics announced that it has received clearance from Australia's TGA and HREC to initiate a Phase 1/2 clinical trial for CMP-002, a therapeutic for SYNGAP1-related diso…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.